Kennedy Capital Management, Inc. Sage Therapeutics, Inc. Transaction History

Kennedy Capital Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$81.94 - $139.71 $2.38 Million - $4.07 Million	-29,102 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $111,730 - $136,753	809 Added 2.86%	29,102 $4.11 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $181,485 - $227,257	1,293 Added 4.79%	28,293 $4.43 Million
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $4.11 Million - $5.19 Million	27,000 New	27,000 $4.35 Million

217

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $414M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.